MTOR and cancer: When this pathway is activated, signaling through Akt extent to some other pathways including PI3K/Akt/mTOR pathway can provide a cancer cell survival, metabolism, proliferation, motility, migration, invasion, and angiogenesis.20 This signaling pathway is seen in approximately 10 % of TNBC patients, especially in mesenchymal and LAR molecular subtypes.21 Ipatasertib is serine/threonine kinase AKT inhibitor.